Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment

NCT01949545 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01949545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01949545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2013
Completion date
September 30, 2015
Enrollment
46 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancies, hepatic impairment, solid tumors